Deciphera Pharmaceuticals Presents: Living with Systemic Mastocytosis (SM) WebEx

Oct 03, 2018

On Tuesday, October 9, 2018, at 11 AM, EDT, Deciphera Pharmaceuticals will be hosting a webinar for the Systemic Mastocytosis (SM) community about Living with Systemic Mastocytosis, and Deciphera Pharmaceuticals’ ongoing clinical trial of DCC-2618, an investigational drug being testing in people with smoldering and advanced forms of Systemic Mastocytosis.

Oliver Rosen, MD, Chief Medical Officer at Deciphera Pharmaceuticals, and Kathy Gram, RN, Head of Patient Advocacy, will present an overview of Deciphera Pharmaceuticals and information about living with SM, as well as previously published data on DCC-2618 and some information about the ongoing clinical trial.

If interested in submitting questions in advance of the webinar please email them to questions@deciphera.com by October 7th.

Webinar connection information:

Viewing Link: https://connectpro48671972.adobeconnect.com/_a984278199/rwkdgtlhc8x4/
Dial-in Number: 1-877-594-8353

Access Code: 46721740

 

After the webinar, a video of the presentation will be available for 30 days, starting on Tuesday, October 16th, at the following link: https://www.deciphera.com/patients/patient-resources/

 

DCC-2618

Deciphera Pharmaceuticals is in Phase 1 of its ongoing expansion clinical trial of treatment with DCC-2618. DCC-2618 is a kinase switch control inhibitor being tested as a potential treatment for gastrointestinal stromal tumors (GISTs), systemic mastocytosis (SM), gliomas, and other solid tumors driven by KIT kinase or PDGFRα kinase.

Deciphera Pharmaceuticals’ goal is to focus on the development of DCC-2618 in patient subgroups where there is a significant unmet medical need.

Approximately 94% of SM patients are reported to have a somatic D816V mutation in KIT. This D816V mutation is a gain-of-function mutation in the KIT activation switch, which leads to unregulated KIT activation. The KIT receptor, which is widely expressed on mast cells, stimulates signaling pathways that control cell growth, differentiation, and survival. The D816V gain-of-function mutation enables mast cells to proliferate in the absence of normal activation signals.

Patients who are interested in exploring participation in the ongoing Phase 1 expansion clinical trial can learn more at clinicaltrials.gov or by emailing Jama Pitman at clinicaltrials@deciphera.com for a referral to a participating trial site.